Is D-Glucitol, 1-deoxy-1-(methylamino)-, (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(4-)-kappan1,kappan4,kappan7,kappan10,kappao1,kappao4,kappao7,kappao10)gadolinate(1-) (1:1) Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use D-Glucitol, 1-deoxy-1-(methylamino)-, (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(4-)-kappan1,kappan4,kappan7,kappan10,kappao1,kappao4,kappao7,kappao10)gadolinate(1-) (1:1)? Is D-Glucitol, 1-deoxy-1-(methylamino)-, (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(4-)-kappan1,kappan4,kappan7,kappan10,kappao1,kappao4,kappao7,kappao10)gadolinate(1-) (1:1) safe for nursing mother and child? Does D-Glucitol, 1-deoxy-1-(methylamino)-, (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(4-)-kappan1,kappan4,kappan7,kappan10,kappao1,kappao4,kappao7,kappao10)gadolinate(1-) (1:1) extracts into breast milk? Does D-Glucitol, 1-deoxy-1-(methylamino)-, (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(4-)-kappan1,kappan4,kappan7,kappan10,kappao1,kappao4,kappao7,kappao10)gadolinate(1-) (1:1) has any long term or short term side effects on infants? Can D-Glucitol, 1-deoxy-1-(methylamino)-, (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(4-)-kappan1,kappan4,kappan7,kappan10,kappao1,kappao4,kappao7,kappao10)gadolinate(1-) (1:1) influence milk supply or can D-Glucitol, 1-deoxy-1-(methylamino)-, (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(4-)-kappan1,kappan4,kappan7,kappan10,kappao1,kappao4,kappao7,kappao10)gadolinate(1-) (1:1) decrease milk supply in lactating mothers?

Gadolinium chelate that has a similar action and use than gadopentetic acid.At latest update no published data on excretion into breast milk were found. It has been used in the pediatric and neonatal age. The various contrast media that are gadolinium derivatives and used for explorations with Magnetic Resonance Imaging (MRI) are considered compatible with breastfeeding because they are quickly eliminated (elimination half-life of less than 2 hours). They undergo very little metabolic changes and are virtually non-absorbable orally. They are structurally very similar to each other. Some have been shown to have no or minimal excretion into the milk. Less than 0.04% of the dose given to the mother ends just going into the milk.Due to its low oral bioavailability, intestinal absorption should be less than 1% of the dose took by the infant.The maximum dose received by the infant is considered less than 0.0004% of the maternal dose, which is much less than the dose administered to a newborn infant who undergoes a MRI scan. Most Radiology Scientific Societies agree that after an MRI scan is not necessary to temporarily stop breastfeeding. Some authors recommend avoiding the use on lactating women of some Gadolinium contrast media that would pose a high risk for developing Systemic Nephrogenic Fibrosis, especially in the neonatal period, like gadoversetamide, and gadodiamide dimeglumine, by using instead low-risk ones like gadoterate, gadoteridol and gadobutrol.

There is no published experience with gadoterate during breastfeeding. Guidelines developed by several professional organizations state that breastfeeding need not be disrupted after a nursing mother receives a gadolinium-containing contrast medium.[1][2][3] Gadoterate is one of the most stable gadolinium agents, theoretically making it one of the safer drugs to use during breastfeeding. However, because there is no published experience with gadoterate during breastfeeding, other agents may be preferred, especially while nursing a newborn or preterm infant.